文献速递前列腺癌

术前穿刺发现前列腺外侵犯的前列腺癌根治术临床、病理与肿瘤学结局

Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
PubMed 文献 · J Urol · 2019-01-01

该回顾性队列纳入83例术前前列腺穿刺即发现前列腺外侵犯并接受根治性前列腺切除术的患者,98%在根治标本中确认外侵犯,59%切缘阳性、45%精囊侵犯、37%淋巴结转移。3年生化复发无生存率为48.4%,3年无转移生存率为75.2%。

要点

  • 穿刺发现前列腺外侵犯者,根治标本几乎均确认外侵犯(98%)。
  • 此类患者不良病理比例高:切缘阳性59%、精囊侵犯45%、淋巴结转移37%。
  • 3年生化复发无生存率仅48.4%,多数需多模式治疗。

核心结论

  • 前列腺穿刺活检发现前列腺外侵犯的患者,根治性前列腺切除标本几乎均存在前列腺外病变且病理结果显著不良。
  • 此类患者中多数出现生化复发,且多数需要多模式治疗。

研究设计与样本

  • 单中心回顾性队列研究,利用机构病理数据库纳入2000至2018年间83例术前穿刺发现前列腺外侵犯、接受根治性前列腺切除术且有临床随访信息的患者。

主要发现

  • 83例中54例(65%)初诊临床分期为T2或更高。
  • 穿刺活检中50例(60%)为Grade Group 4-5,66例(81%)存在神经周围侵犯。
  • 根治标本中81例(98%)确认前列腺外侵犯,49例(59%)切缘阳性,37例(45%)精囊侵犯,30例(37%)淋巴结受累。
  • 术后中位随访2年,76例中34例(45%)接受术后放疗(中位时间根治术后1年),8例(11%)接受化疗(中位时间根治术后2年)。
  • 3年生化复发无生存率为48.4%(95%CI 0.345-0.610),3年无转移生存率为75.2%(95%CI 0.603-0.851)。

临床怎么用

  • 术前穿刺发现前列腺外侵犯可提示根治术后病理不良风险高,可用于术前咨询治疗方式与预期结局。
  • 对此类患者应预期较高的生化复发风险及多模式治疗需求。

局限性

  • 单中心回顾性研究,样本量83例,随访中位时间仅2年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostatic adenocarcinoma with extraprostatic extension detected on prostate needle biopsy is an uncommon finding. We describe clinical and pathological findings in a large cohort of patients with prostatic adenocarcinoma who were treated with radical prostatectomy and in whom extraprostatic extension was identified on prostate needle biopsy. MATERIALS AND METHODS: Using our institutional pathology database we identified 83 patients with prostatic adenocarcinoma and with extraprostatic extension on prostate needle biopsy between 2000 to 2018 who underwent radical prostatectomy and had clinical followup information. Clinical and pathological outcomes were examined. RESULTS: Of the 83 patients 54 (65%) presented with clinical stage T2 or greater disease. On biopsy 50 of the 83 patients (60%) had Grade Group 4-5 and 66 (81%) had perineural invasion. Extraprostatic extension was confirmed in the radical prostatectomy specimen in 81 of 83 cases (98%). At radical prostatectomy 49 of 83 patients (59%) had positive surgical margins, 37 (45%) had seminal vesicle invasion and 30 (37%) had lymph node involvement. Median followup after radical prostatectomy was 2 years. Overall 34 of 76 men (45%) received postoperative radiation a median of 1 year after radical prostatectomy and 8 (11%) received chemotherapy a median of 2 years after radical prostatectomy. The 3-year biochemical recurrence-free survival rate was 48.4% (95% CI 0.345-0.610) and the 3-year metastasis-free survival rate was 75.2% (95% CI 0.603-0.851). CONCLUSIONS: Patients in whom extraprostatic extension is detected on prostate needle biopsy almost always have extraprostatic disease and markedly adverse pathology findings at radical prostatectomy. Many of them experience biochemical recurrence and most will require multimodal therapy. These data can be useful to counsel such patients in regard to the treatment approach and the expected outcomes after surgery.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Faisal FA, Tosoian JJ, Han M, et al. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. J Urol. 2019. PMID: 30414957. doi:10.1016/j.juro.2018.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。